Basic Information
| LncRNA/CircRNA Name | circUBAP2 |
| Synonyms | circ_0001846 |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | CCK-8 and EDU assays, Transwell migration assay, Apoptosis analysis, qRT-PCR, FISH, circRIP, Luciferase activity assay |
| Sample | TNBC tissues, breast cancer cells MCF-10A, T47D, BT-20, SK-BR-3, MCF-7, MDA-MB-468, and MDA-MB-231 |
| Expression Pattern | up-regulated |
| Function Description | a novel circRNA, circ-UBAP2 (hsa_circ_0001846), was shown to be markedly upregulated in TNBC. Functionally, lentivirus-mediated stable knockdown of circ-UBAP2 dramatically weakened the ability of TNBC cells to proliferate and migrate and induced apoptosis in vitro and in vivo. Regarding the mechanism, we found that circ-UBAP2 was mainly observed in the cytoplasm and was capable of sponging miRNA-661 to increase the expression of the oncogene MTA1. Additionally, silencing of miRNA-661 or overexpression of MTA1 could partially rescue the attenuated malignant phenotype caused by circ-UBAP2 knockdown. |
| Pubmed ID | 30314706 |
| Year | 2018 |
| Title | Upregulation of circ-UBAP2 predicts poor prognosis and promotes triple-negative breast cancer progression through the miR-661/MTA1 pathway |
External Links
| Links for circUBAP2 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |